Elite Journal of Laboratory Medicine. Volume 2 issue 3(2024), Pp. 1-0
https://epjournals.com/journals/EJLM

Reactive Oxygen Species and Antioxidant Defense Mechanisms in Sickle Cell Anemia: A Review

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[3]School of Nursing Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Sickle cell anemia (SCA) is a genetic hemoglobinopathy characterized by abnormal hemoglobin S (HbS) production, leading to the formation of sickle-shaped red blood cells. Oxidative stress, resulting from the imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms, plays a pivotal role in the pathophysiology of SCA. This comprehensive review examines the mechanisms underlying oxidative stress in SCA, including sources of ROS production and the role of antioxidant defense mechanisms. Furthermore, the review explores the implications of oxidative stress for disease severity and complications in SCA and discusses current therapeutic strategies targeting oxidative stress. Understanding the complex interplay between ROS production and antioxidant defenses is critical for developing effective therapeutic interventions to mitigate oxidative stress and improve outcomes in SCA. Further research is warranted to elucidate the efficacy and safety of existing and emerging therapeutic approaches, with the ultimate goal of enhancing the quality of life for individuals living with SCA.

Keywords: *Reactive Oxygen Species, Antioxidant Defense Mechanisms, Sickle Cell Anemia, Oxidative Stress, Redox Imbalance, Hydroxyurea, Transfusion Therapy*

Introduction

Sickle cell anemia (SCA) stands as one of the most prevalent inherited blood disorders worldwide, characterized by the production of abnormal hemoglobin S (HbS) leading to erythrocyte deformation into a characteristic sickle shape. While the primary pathophysiological hallmark of

Citation: Obeagu EI, Obeagu GU. Reactive Oxygen Species and Antioxidant Defense Mechanisms in Sickle Cell Anemia: A Review. Elite Journal of Laboratory Medicine, 2024; 2(3): 1-10

SCA involves the polymerization of deoxygenated HbS and the consequential sickling of erythrocytes, emerging evidence underscores the pivotal role of oxidative stress in exacerbating disease severity and complications. Oxidative stress arises from the dysregulated production of reactive oxygen species (ROS) overwhelming antioxidant defense mechanisms, thereby inducing cellular damage and contributing to the multi-organ manifestations observed in SCA. The interplay between ROS production and antioxidant defense mechanisms forms the crux of the oxidative stress cascade in SCA. Multiple sources contribute to ROS generation in SCA, encompassing intravascular hemolysis, ischemia-reperfusion injury, inflammation, and the activation of leukocytes and platelets. Furthermore, the unique pathological milieu of SCA, characterized by chronic hemolysis, endothelial dysfunction, and vascular inflammation, exacerbates ROS production and perpetuates oxidative stress. Antioxidant defense mechanisms, including enzymatic and non-enzymatic antioxidants, act in concert to neutralize ROS and mitigate cellular damage. However, the balance between ROS production and antioxidant defenses is often disrupted in SCA, leading to oxidative damage to lipids, proteins, and DNA.[1-22]

The implications of oxidative stress in SCA extend beyond cellular damage to encompass disease severity and complications. Oxidative stress contributes to the pathogenesis of vaso-occlusive crises, acute chest syndrome, pulmonary hypertension, and endothelial dysfunction, thereby exacerbating morbidity and mortality in SCA. ROS-mediated endothelial dysfunction promotes inflammation, platelet activation, and adhesion molecule expression, culminating in vaso-occlusion and tissue ischemia. Moreover, oxidative stress impairs nitric oxide bioavailability, exacerbating endothelial dysfunction and contributing to the development of pulmonary hypertension, a leading cause of mortality in SCA. Current therapeutic strategies for SCA aim to mitigate oxidative stress and its associated complications. Hydroxyurea, a disease-modifying agent, enhances fetal hemoglobin production, reduces hemolysis, and alleviates oxidative stress in SCA. Additionally, transfusion therapy provides healthy red blood cells with normal hemoglobin, reducing HbS polymerization and ROS production. Furthermore, antioxidant supplementation, such as vitamin E and N-acetylcysteine, may complement existing therapies by bolstering antioxidant defenses and mitigating oxidative stress in SCA. However, further research is needed to elucidate the efficacy and safety of these therapeutic approaches, with the ultimate goal of improving outcomes and enhancing the quality of life for individuals living with SCA.[23-39]

Reactive Oxygen Species Production in Sickle Cell Anemia

Reactive oxygen species (ROS) production is a hallmark feature of sickle cell anemia (SCA), contributing significantly to its pathophysiology and associated complications. Multiple sources contribute to ROS generation in SCA, creating a complex interplay of oxidative stress within the body. Intravascular hemolysis, a prominent characteristic of SCA, leads to the release of hemoglobin and heme into the bloodstream, where they undergo auto-oxidation, generating superoxide radicals and hydrogen peroxide. Furthermore, ischemia-reperfusion injury, occurring during vaso-occlusive events, exacerbates ROS production as tissues undergo cycles of hypoxia and reoxygenation, triggering oxidative damage to endothelial cells and surrounding tissues. Inflammation plays a crucial role in ROS production in SCA, with activated leukocytes and

platelets releasing inflammatory mediators and producing ROS as part of the immune response. Leukocytes adhere to endothelial cells, further promoting inflammation and ROS production, contributing to the perpetuation of oxidative stress in SCA. Additionally, activated platelets release ROS and pro-inflammatory cytokines, exacerbating vascular dysfunction and promoting vaso-occlusion. The presence of sickle-shaped red blood cells further exacerbates oxidative stress by promoting vascular endothelial dysfunction, increasing adhesion molecule expression, and releasing pro-inflammatory cytokines, perpetuating a vicious cycle of inflammation and ROS production.[40-55]

Moreover, the activation of specific enzymes, such as NADPH oxidase and xanthine oxidase, contributes to ROS production in SCA. NADPH oxidase, present in leukocytes and endothelial cells, generates superoxide radicals as part of the respiratory burst during phagocytosis and inflammation. Xanthine oxidase, activated during ischemia-reperfusion injury and tissue hypoxia, catalyzes the conversion of hypoxanthine to xanthine and subsequently to uric acid, generating superoxide radicals and hydrogen peroxide in the process. Additionally, mitochondrial dysfunction, often observed in SCA, leads to the generation of ROS as a byproduct of oxidative phosphorylation, further contributing to oxidative stress and cellular damage. The cumulative effect of ROS production in SCA results in widespread oxidative damage to lipids, proteins, and DNA, exacerbating disease severity and complications. Lipid peroxidation, protein oxidation, and DNA damage contribute to endothelial dysfunction, inflammation, and vaso-occlusive events, perpetuating tissue injury and organ damage in SCA. Understanding the sources and mechanisms of ROS production in SCA is crucial for developing targeted therapeutic interventions aimed at mitigating oxidative stress and improving outcomes in individuals living with this debilitating disorder.[56-62]

Antioxidant Defense Mechanisms in Sickle Cell Anemia

Antioxidant defense mechanisms play a critical role in counteracting the oxidative stress observed in sickle cell anemia (SCA), helping to mitigate the damaging effects of reactive oxygen species (ROS) and maintain cellular homeostasis.[63] These defense mechanisms encompass a diverse array of enzymatic and non-enzymatic antioxidants that work in concert to neutralize ROS and protect cells from oxidative damage. Enzymatic antioxidants, including superoxide dismutase (SOD), catalase, and glutathione peroxidase, play key roles in scavenging ROS and preventing their harmful effects. SOD catalyzes the dismutation of superoxide radicals into hydrogen peroxide and oxygen, thereby reducing the levels of superoxide within cells. Catalase and glutathione peroxidase further metabolize hydrogen peroxide, converting it into water and oxygen, thereby preventing the formation of highly reactive hydroxyl radicals. Non-enzymatic antioxidants, such as glutathione, vitamin E, vitamin C, and bilirubin, also play crucial roles in protecting cells from oxidative damage. Glutathione acts as a potent antioxidant by directly scavenging ROS and regenerating other antioxidants, such as vitamin C and vitamin E, thereby maintaining their antioxidant capacity. Vitamin E, a lipid-soluble antioxidant, protects cell membranes from lipid peroxidation by scavenging lipid-derived free radicals. Vitamin C, a water-soluble antioxidant, regenerates vitamin E and neutralizes ROS in aqueous compartments of cells. Bilirubin, a

breakdown product of heme, possesses antioxidant properties and helps protect cells from oxidative damage. Additionally, the redox balance within cells is tightly regulated by the thiol-disulfide exchange system, which maintains the levels of reduced and oxidized forms of glutathione, thioredoxin, and other thiol-containing molecules. This system helps ensure proper cellular function and protects cells from oxidative stress-induced damage. Despite the presence of robust antioxidant defense mechanisms, individuals with SCA often experience oxidative stress due to the overwhelming production of ROS and the depletion of antioxidant reserves. Chronic hemolysis, inflammation, and ischemia-reperfusion injury further exacerbate oxidative stress in SCA, overwhelming antioxidant defenses and leading to cellular damage and organ dysfunction.

Implications for Disease Severity and Complications

The implications of oxidative stress in sickle cell anemia (SCA) extend beyond cellular damage to encompass disease severity and a wide range of complications that significantly impact patient outcomes. Oxidative stress contributes to the pathogenesis of vaso-occlusive crises, acute chest syndrome, pulmonary hypertension, endothelial dysfunction, and other complications associated with SCA.[64] Vaso-occlusive crises are hallmark features of SCA, characterized by the occlusion of small blood vessels by sickle-shaped red blood cells, leading to tissue ischemia and organ damage. Oxidative stress exacerbates vaso-occlusive events by promoting endothelial dysfunction, inflammation, and adhesion molecule expression, thereby enhancing the adhesion of sickle cells to endothelial surfaces and exacerbating tissue ischemia and pain. Acute chest syndrome (ACS) represents a life-threatening complication of SCA, characterized by pulmonary inflammation, hypoxia, and respiratory distress. Oxidative stress plays a significant role in the pathogenesis of ACS, promoting endothelial dysfunction, leukocyte activation, and inflammation within the pulmonary vasculature. ROS-induced damage to endothelial cells and disruption of the pulmonary microvasculature contribute to the development of ACS and its associated morbidity and mortality.

Pulmonary hypertension is a common complication of SCA and a leading cause of mortality in affected individuals. Oxidative stress contributes to the pathogenesis of pulmonary hypertension by impairing nitric oxide bioavailability, promoting vasoconstriction, and exacerbating vascular remodeling.[65] ROS-induced endothelial dysfunction and smooth muscle cell proliferation further contribute to the progression of pulmonary hypertension, leading to right heart failure and reduced life expectancy in individuals with SCA. Endothelial dysfunction is a central feature of SCA pathophysiology and contributes to the development of vaso-occlusive events, ACS, pulmonary hypertension, and other complications. Oxidative stress disrupts endothelial cell function by promoting inflammation, oxidative damage, and impaired nitric oxide signaling, leading to vasoconstriction, platelet activation, and enhanced adhesion molecule expression. Endothelial dysfunction contributes to the prothrombotic and proinflammatory state observed in SCA, exacerbating tissue ischemia and organ damage. Overall, oxidative stress plays a pivotal role in the pathogenesis of complications associated with SCA, contributing to disease severity and significantly impacting patient outcomes. Strategies aimed at mitigating oxidative stress and restoring redox balance may hold promise for improving outcomes and reducing the burden of complications in individuals living with SCA. However, further research is needed to elucidate the

efficacy and safety of these interventions and their potential impact on disease progression and long-term outcomes.

Therapeutic Strategies Targeting Oxidative Stress in Sickle Cell Anemia

Therapeutic strategies targeting oxidative stress in sickle cell anemia (SCA) aim to mitigate the damaging effects of reactive oxygen species (ROS) and restore redox balance, thereby alleviating disease severity and reducing the risk of complications.[66-67] These strategies encompass a diverse array of approaches, including pharmacological agents, dietary interventions, and lifestyle modifications, all aimed at reducing oxidative stress and improving outcomes in individuals with SCA. Hydroxyurea stands as the cornerstone of pharmacological therapy for SCA, exerting its beneficial effects by increasing fetal hemoglobin (HbF) production, reducing hemolysis, and ameliorating oxidative stress. Hydroxyurea promotes the expression of HbF, a less polymerizable form of hemoglobin, thereby reducing the proportion of sickle hemoglobin (HbS) within red blood cells and mitigating HbS polymerization-induced oxidative stress. Additionally, hydroxyurea exhibits anti-inflammatory and vasodilatory properties, further contributing to its beneficial effects in SCA.

Transfusion therapy represents another therapeutic approach for reducing oxidative stress in SCA by providing healthy red blood cells with normal hemoglobin, thereby diluting the proportion of sickle hemoglobin and reducing the risk of vaso-occlusive events.[68] Red blood cell transfusions help improve oxygen delivery to tissues, reduce hemolysis, and mitigate oxidative stress-induced tissue damage. However, the long-term use of transfusion therapy may be associated with iron overload and other complications, necessitating careful monitoring and management. Antioxidant supplementation, including vitamins E and C, N-acetylcysteine, and other antioxidants, represents a promising adjunctive therapy for reducing oxidative stress in SCA. These antioxidants scavenge ROS, neutralize free radicals, and protect cells from oxidative damage, thereby mitigating disease severity and reducing the risk of complications. However, the efficacy of antioxidant supplementation in SCA remains controversial, and further research is needed to elucidate its therapeutic potential and optimal dosing regimens. Dietary interventions aimed at enhancing antioxidant intake, such as consuming a diet rich in fruits, vegetables, and whole grains, may help reduce oxidative stress and improve outcomes in individuals with SCA. These foods are rich in vitamins, minerals, and phytochemicals with antioxidant properties, which can help neutralize ROS and protect cells from oxidative damage. Additionally, lifestyle modifications, such as regular physical activity, stress management, and avoidance of environmental triggers, may further complement therapeutic interventions by reducing oxidative stress and promoting overall health and well-being in individuals with SCA.

Conclusion

Oxidative stress plays a central role in the pathophysiology of sickle cell anemia (SCA), contributing significantly to disease severity and associated complications. The imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms leads to

cellular damage, inflammation, and endothelial dysfunction, exacerbating vaso-occlusive events, acute chest syndrome, pulmonary hypertension, and other complications observed in SCA. Therapeutic strategies targeting oxidative stress, such as hydroxyurea, transfusion therapy, and antioxidant supplementation, hold promise for reducing disease severity and improving outcomes in individuals with SCA. Hydroxyurea promotes the expression of fetal hemoglobin (HbF), reduces hemolysis, and ameliorates oxidative stress, while transfusion therapy provides healthy red blood cells with normal hemoglobin, reducing the proportion of sickle hemoglobin and mitigating oxidative stress-induced tissue damage. Antioxidant supplementation scavenges ROS, neutralizes free radicals, and protects cells from oxidative damage, further complementing existing therapies.

References

1. Bhawnani K, Yadav R. An Overview on Sickle Cell Anaemia. Journal of Pharmaceutical Negative Results. 2023:2069-2080.
2. Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annual review of genomics and human genetics. 2018; 19:113-47.
3. Arishi WA, Alhadrami HA, Zourob M. Techniques for the detection of sickle cell disease: a review. Micromachines. 2021;12(5):519.
4. Fasano RM, Meier ER, Chonat S. Sickle cell disease, thalassemia, and hereditary hemolytic anemias. Rossi's Principles of Transfusion Medicine. 2022:326-345.
5. Wonkam A. Perspectives Chapter 14 in genomics and sickle cell disease therapeutics. Molecular Hematology. 2024:187.
6. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
7. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
8. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
9. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
10. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-17.
11. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
12. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-8.
13. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
14. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP. Men's Essential roles in the Management of Sickle Cell Anemia. **NEWPORT INTERNATIONAL JOURNAL OF**

SCIENTIFIC AND EXPERIMENTAL SCIENCES 4(2):20-29. https://doi.org/10.59298/NIJSES/2023/10.3.1111

15. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
16. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
17. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
18. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Alum EU, Ugwu OP. Antioxidants and Pregnancy: Impact on Maternal and Fetal Health. APPLIED SCIENCES (NIJBAS). 2023;4(1).
19. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023;6(4):12-7.
20. Obeagu EI, Ubosi NI, Uzoma G. Antioxidant Supplementation in Pregnancy: Effects on Maternal and Infant Health. Int. J. Adv. Multidiscip. Res. 2023;10(11):60-70.
21. Obeagu EI, Obeagu GU. Utilization of Antioxidants in the management of diabetes mellitus patients. J Diabetes Clin Prac. 2018;1(102):2.
22. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.
23. Öztaş Y, Boşgelmez İİ. Oxidative stress in sickle cell disease and emerging roles for antioxidants in treatment strategies. InPathology 2020: 65-75. Academic Press.
24. Silva M, Faustino P. From stress to sick (le) and back again–oxidative/antioxidant mechanisms, genetic modulation, and cerebrovascular disease in children with sickle cell anemia. Antioxidants. 2023;12(11):1977.
25. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023;102(48):e36462.
26. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
27. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
28. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med. 2023;1:1-7.
29. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
30. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
31. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.

Citation: Obeagu EI, Obeagu GU. Reactive Oxygen Species and Antioxidant Defense Mechanisms in Sickle Cell Anemia: A Review. Elite Journal of Laboratory Medicine, 2024; 2(3): 1-10

32. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
33. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
34. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
35. Nwosu DC, Obeagu EI, Ezenwuba C, Agu GC, Amah H, Ozims SJ, Nwanjo HU, Edward A, Izuchukwu IF, Amadike JN, Nwagwu AJ. Antioxidant status of children with Plasmodium falciparum malaria in Owerri municipal council of Imo state. Int. J. Curr. Res. Chem. Pharm. Sci. 2016;3(8):40-6.
36. Ezimah UA, Obeagu EI, Ezimah CO, Ezimah A, Nto NJ. Diarrhoeal diseases of acquired immunodeficiency syndrome stimulate more depletion of total antioxidant status. Int. J. Adv. Multidiscip. Res. 2016;3(4):23-5.
37. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-7.
38. Alum EU, Aja W, Ugwu OP, Obeagu EI, Okon MB. Assessment of vitamin composition of ethanol leaf and seed extracts of datura stramonium. Avicenna J Med Biochem. 2023;11(1):92-7.
39. Alum EU, Inya JE, Ugwu OP, Obeagu EI, Aloke C, Aja PM, Okpata MG, John EC, Orji MO, Onyema O. Ethanolic leaf extract of Datura stramonium attenuates methotrexate-induced biochemical alterations in Wistar Albino rats. RPS Pharmacy and Pharmacology Reports. 2023;2(1): rqac011.
40. Antwi-Boasiako C, B. Dankwah G, Aryee R, Hayfron-Benjamin C, S. Donkor E, D. Campbell A. Oxidative profile of patients with sickle cell disease. Medical Sciences. 2019 ;7(2):17.
41. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF ENZYME ANTIOXIDANTS IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. European Journal of Biomedical. 2020;7(11):285-8.
42. Ifeanyi OE. A review on free radicals and antioxidants. Int. J. Curr. Res. Med. Sci. 2018;4(2):123-33.
43. Akinpelu M, Gamade SM, Akinbo F, Adeniyi TD, Elizebeth AF, Obeagu EI. Histopathological and Biochemical Effect of Vitamin C and D on Phosphine-Induced Hepatotoxicity in Wistar Rats. Asian Journal of Dental and Health Sciences. 2023;3(2):18-22.
44. Nwakulite A, Obeagu EI, Eze R, Ugochi VE, Vincent CC, Okafor CJ, Chukwurah EF, Unaeze BC, Amaechi CO, Okwuanaso CB, Chukwuani U. Estimation of Serum

Glutathione Peroxidase in Streptozotocin Induced Diabetic Rat Treated with Bitter Leaf Extract. Journal of Pharmaceutical Research International. 2021;33(30B):200-6.
45. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In the Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 S.
46. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
47. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
48. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
49. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
50. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
51. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
52. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-14.
53. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10; 6 (2): 10-13.
54. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
55. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
56. Chaves NA, Alegria TG, Dantas LS, Netto LE, Miyamoto S, Domingos CR, da Silva DG. Impaired antioxidant capacity causes a disruption of metabolic homeostasis in sickle erythrocytes. Free Radical Biology and Medicine. 2019; 141:34-46.
57. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-143.
58. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
59. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of

Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
60. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
61. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
62. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
63. Engwa GA, Okolie A, Chidili JP, Okore PA, Onu PC, Ugwu MO, Oko DE, Ferdinand PU. Relationship of oxidative stress and antioxidant response with vaso-occlusive crisis in sickle cell anaemia. African Health Sciences. 2021;21(1):150-158.
64. Silva M, Faustino P. From stress to sick (le) and back again–oxidative/antioxidant mechanisms, genetic modulation, and cerebrovascular disease in children with sickle cell anemia. Antioxidants. 2023 Nov 7;12(11):1977.
65. Wood KC, Gladwin MT, Straub AC. Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure. Heart. 2020;106(8):562-568.
66. Bell V, Varzakas T, Psaltopoulou T, Fernandes T. Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions. Nutrients. 2024;16(2):258.
67. Bou-Fakhredin R, De Franceschi L, Motta I, Eid AA, Taher AT, Cappellini MD. Redox balance in β-thalassemia and sickle cell disease: a love and hate relationship. Antioxidants. 2022;11(5):967.
68. Mandal AK, Mitra A, Das R. Sickle cell hemoglobin. Vertebrate and Invertebrate Respiratory Proteins, Lipoproteins and other Body Fluid Proteins. 2020:297-322.